Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYargenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual MeetingPREV STORYImmuron CEO to Present at RedChip Global Online Growth Conference